Naira Asatrian
Surgical · Fresno, CANPI 1912153131
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.2% of the total across 260 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 13.1% — the pattern of someone who eats at a lot of different presentations. Among surgical clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 260 payments — averaging $37.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$1K
- Amgen$1K
- Novo Nordisk$1K
- AstraZeneca$1K
- Lilly USA, LLC$806
- Bayer$614
- plus $4K from 28 others
What the payments were for
- Consulting fees$1752%
- Food & beverage$9,53598%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 42 | $1,270 |
| Amgen(2 entities) | 33 | $1,195 |
| Novo Nordisk | 37 | $1,024 |
| AstraZeneca | 45 | $1,011 |
| Lilly USA, LLC | 15 | $806 |
| Bayer | 17 | $614 |
| AbbVie | 13 | $453 |
| GSK | 6 | $392 |
| Phathom Pharmaceuticals, Inc. | 3 | $375 |
| Otsuka America Pharmaceutical, Inc. | 3 | $162 |
| Biohaven Pharmaceuticals, Inc. | 3 | $158 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $147 |
| Kowa Pharmaceuticals America, Inc. | 2 | $141 |
| Neurocrine Biosciences, Inc. | 1 | $140 |
| Agios Pharmaceuticals, Inc. | 1 | $137 |
| Abbott | 3 | $135 |
| Aimmune Therapeutics, Inc. | 1 | $124 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $123 |
| Intercept Pharmaceuticals, Inc. | 1 | $123 |
| Ipsen Biopharmaceuticals, Inc | 1 | $122 |
| Madrigal Pharmaceuticals | 1 | $121 |
| Vanda Pharmaceuticals Inc. | 5 | $118 |
| Pfizer | 7 | $116 |
| Regeneron Healthcare Solutions, Inc. | 1 | $108 |
| Abiomed | 1 | $101 |
| Gilead | 1 | $100 |
| Neurelis, Inc. | 1 | $95 |
| Esperion Therapeutics, Inc. | 2 | $67 |
| Ironwood Pharmaceuticals, Inc | 3 | $58 |
| Daiichi Sankyo Inc. | 3 | $57 |
| Shield Therapeutics Inc | 2 | $41 |
| Nevro Corp. | 1 | $35 |
| Exact Sciences | 1 | $26 |
| Mylan Specialty L.p. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,710 in reported general payments places this provider in the 95th percentile of 729 surgical providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 168 | $218,950 |
| JardianceEmpagliflozin | 123 | $119,920 |
| JanuviaSitagliptin Phosphate | 83 | $80,551 |
| TrulicityDulaglutide | 50 | $53,986 |
| FarxigaDapagliflozin Propanediol | 32 | $40,751 |
| RybelsusSemaglutide | 31 | $34,276 |
| EliquisApixaban | 45 | $32,056 |
| LinzessLinaclotide | 36 | $27,836 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 41 | $27,409 |
| MounjaroTirzepatide | 21 | $20,989 |
| TradjentaLinagliptin | 26 | $14,276 |
| MyrbetriqMirabegron | 23 | $11,859 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 31 | $10,770 |
| VascepaIcosapent Ethyl | 17 | $7,859 |
| ElmironPentosan Polysulfate Sodium | 13 | $6,171 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,024 | $253,226199 claims |
| Boehringer IngelheimJardiance, Tradjenta | $1,270 | $134,197149 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $806 | $74,97571 claims |
| AstraZenecaFarxiga | $1,011 | $40,75132 claims |
| PfizerEliquis | $116 | $32,05645 claims |
| AbbVieLinzess, Synthroid | $453 | $28,97753 claims |
| GSKTrelegy Ellipta | $392 | $27,40941 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 729 surgical providers in California.
Other surgical in Fresno
- Tuantu Doan VuFresno$6K
- Brittany CoxFresno$5K
- Lauren AmicoVista$989K
- Cheyanne MallasWest Hollywood$199K
- Laura PietrzakMarina del Rey$63K
- Jane HartiganSanta Rosa$27K
- Kenny NgoPalo Alto$25K
- Crispin MarRancho Santa Margarita$23K
- Robert FrostRancho Santa Margarita$22K
- Audie LeeSan Francisco$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.